People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Other Technology, Software / Tech, Other, Environmental Services
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ImmunityBio, Inc. | — | Biotechnology | Growth/Late | $640.1M | $7.8B | 2022 |
| Axonius, Inc. | — | Other Technology | Series D+ | $570.5M | $705.0M | 2020 |
| Digital Reasoning Systems, Inc. | — | Software / Tech | Series B | $80.5M | $913.8M | 2011 |
| Avi-Spl Holdings, Inc. | — | Other | Series A | $28.0M | $227.0M | 2009 |
| Buildium, LLC | — | Other Technology | Series B | $18.8M | $572.2M | 2016 |
| Momento Market, Inc. | — | Other Technology | Series A | $9.9M | $154.3M | 2021 |
| FINEOS Corp Holdings PLC | — | Other Technology | Series A | $8.3M | $218.6M | 2020 |
| HereNow Help, Inc. | — | Other Technology | Seed | $6.4M | $16.6M | 2019 |
| Exacter, Inc. | — | Environmental Services | Seed | $3.0M | $82.7M | 2013 |
John Brennan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Brennan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Soon-Shiong | 1 | 16 |
| Michael Kelly | 1 | 11 |
| Jodi Hubler | 1 | 8 |
| Ajay Shah | 1 | 7 |
| Wesley Clark | 1 | 7 |
| Brett Jackson | 1 | 5 |
| Jonathan T. Lord | 1 | 5 |
| David Sachs | 1 | 5 |
| John C. Thomas, Jr. | 1 | 5 |
| Cristobal Conde | 1 | 4 |
| Rana Yared | 1 | 4 |
| Cheryl Cohen | 1 | 3 |
| Prakash Ramachandran | 1 | 3 |
| Mark Daniel | 1 | 3 |
| Tal Morgenstern | 1 | 3 |
| Kenneth Fox | 1 | 3 |
| David Hollander | 1 | 3 |
| Steve J. Gorlin | 1 | 3 |
| Barry Simon | 1 | 3 |
| Robert Metcalf | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.